Non-Alcoholic Fatty Liver Disease
Conditions
Keywords
Steatohepatitis, Smoking, Aminotransferase
Brief summary
This non-randomized clinical trial was performed to clarify the effect of cigarette smoking reduction on liver function and some anthropocentric indices in smoker patients with non-alcoholic steatohepatitis.
Detailed description
After excluding other causes of high aminotransferase level, participants with persistent elevated serum aminotransferase levels and evidence of fatty liver in ultrasonography were presumed to have non-alcoholic steatohepatitis. Those with NAFLD liver fat score greater than (-0.64) were enrolled. They were assigned to lifestyle modification alone or lifestyle modification plus smoking reduction groups. Liver fat content, fasting serum glucose, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, triglyceride, cholesterol, high and low-density lipoprotein, homeostasis model assessment-insulin resistance(HOMA-IR), and anthropometric measurements (body mass index and waist circumference) were checked at baseline and six months later.
Interventions
BEHAVIORALMotivational interviewing
Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight
Sponsors
Tehran University of Medical Sciences
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Smokers with persistent elevated aminotransferase levels with the evidence of fatty liver in ultrasonography, who were referred to a gastroenterology clinic.
Exclusion criteria
* alcohol use (more than 20 gram per day in men and 10 gram per day in women per day), * heart disease (ischemic or congestive), * hepatic disease (viral hepatitis, autoimmune hepatitis, wilson disease, hemochromatosis, liver mass lesion), * renal disease (serum creatinine concentration of \> 1.5 mg/dl), * any severe systemic co-morbidities, neoplasm, * using any hepatotoxic medication during the past 3 months, * pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Liver fat content percent change from baseline to 6 months | 6 months | Liver fat content percent changes calculated by a formula |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum alanine aminotransferase level changes form baseline to 6 months | 6 months | International unit per liter, Minimum value: 0, higher values show worse outcome |
Other
| Measure | Time frame | Description |
|---|---|---|
| Serum aspartate aminotransferase level changes form baseline to 6 months | 6 months | International unit per liter, Minimum value: 0, higher values show worse outcome |
Countries
Iran
Outcome results
None listed